Those are the types of clues Eli Lillys CEO, David Ricks, says his company will pursue next year, testing whether its GLP-1 drug, tirzepatide (called Mounjaro for diabetes treatment, and Zepbound for weight loss), could help with addiction to alcohol, nicotine, and other things we dont think about [as being] connected to weight. In comments he made in December, Ricks said the drugs might be anti-hedonicsmeaning they counteract our hedonistic pursuit of pleasure, be it from food, alcohol, or drugs
High intensity exercise inhibits carnitine palmitoyltransferase-I sensitivity to [PMID: 30635360] Laboratory literature summary: High intensity exercise inhibits carnitine palmitoyltransferase-I sensitivity to l-carnitine
What they're saying: "Now think of that, $50 a month
If you have Type 2 diabetes, ask your Kaiser endocrinologist about Mounjaroyou may have a coverage pathway that doesn't exist for weight loss